LGASX
Price
$74.46
Change
-$0.26 (-0.35%)
Updated
Jul 31 closing price
Net Assets
705.48M
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

LGASX vs VSCIX

LGASX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
LGASX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LGASX is a Buy and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. LGASX (705M). VSCIX pays higher dividends than LGASX: VSCIX (1.23) vs LGASX (0.10). LGASX was incepted earlier than VSCIX: LGASX (22 years) vs VSCIX (29 years). LGASX (1.40) is less costly to investors than VSCIX (0.03). LGASX is a more actively managed with annual turnover of: 33.00 vs. VSCIX (17.00). LGASX has a lower initial minimum investment than VSCIX: LGASX (0) vs VSCIX (5000000). VSCIX annual gain was more profitable for investors over the last year : 22.58 vs. LGASX (17.97). VSCIX return over 5 years is better than : 35.13 vs. LGASX (2.12).
LGASXVSCIXLGASX / VSCIX
Total Expense Ratio1.070.033,567%
Annual Report Gross Expense Ratio1.400.034,667%
Fund Existence22 years29 years-
Gain YTD15.46014.591106%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets705M189B0%
Annual Yield % from dividends0.101.238%
Returns for 1 year17.9722.5880%
Returns for 3 years19.2743.4444%
Returns for 5 years2.1235.136%
Returns for 10 years54.30156.0735%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C